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Discriminating radiation injury from
recurrent tumor with [18F]PARPi and amino
acid PET in mouse models
Patrick L. Donabedian1, Susanne Kossatz1, John A. Engelbach2, Stephen A. Jannetti1,4,5, Brandon Carney1,4,6,
Robert J. Young1,7, Wolfgang A. Weber1,8,9, Joel R. Garbow2,3 and Thomas Reiner1,7*
Abstract
Background: Radiation injury can be indistinguishable from recurrent tumor on standard imaging. Current
protocols for this differential diagnosis require one or more follow-up imaging studies, long dynamic acquisitions,
or complex image post-processing; despite much research, the inability to confidently distinguish between these
two entities continues to pose a significant dilemma for the treating clinician. Using mouse models of both
glioblastoma and radiation necrosis, we tested the potential of poly(ADP-ribose) polymerase (PARP)-targeted PET
imaging with [18F]PARPi to better discriminate radiation injury from tumor.
Results: In mice with experimental radiation necrosis, lesion uptake on [18F]PARPi-PET was similar to contralateral
uptake (1.02 ± 0.26 lesion/contralateral %IA/ccmax ratio), while [
18F]FET-PET clearly delineated the contrast-enhancing
region on MR (2.12 ± 0.16 lesion/contralateral %IA/ccmax ratio). In mice with focal intracranial U251 xenografts, tumor
visualization on PARPi-PET was superior to FET-PET, and lesion-to-contralateral activity ratios (max/max, p = 0.034) were
higher on PARPi-PET than on FET-PET.
Conclusions: A murine model of radiation necrosis does not demonstrate [18F]PARPi avidity, and [18F]PARPi-PET is
better than [18F]FET-PET in distinguishing radiation injury from brain tumor. [18F]PARPi-PET can be used for
discrimination between recurrent tumor and radiation injury within a single, static imaging session, which may be of
value to resolve a common dilemma in neuro-oncology.
Keywords: PET/CT, PARP1, Radiation necrosis, Radiation injury, Amino acid PET, Biomarkers
Background
Treatment of glioblastoma generally proceeds with surgi-
cal debulking or resection followed by adjuvant chemo-
therapy, usually including temozolomide, and whole-brain
or targeted radiation therapy [1]. A frequent and problem-
atic development in the management of patients with
brain cancer post-radiotherapy is the appearance of an
increased or new enhancing lesion within the radiation
field, which could be either a recurrent tumor or radiation
injury [2]. Radiation injury spans a spectrum from the
clinically defined “pseudoprogression,” which is early,
self-limiting, and spontaneously resolving, to radiation
necrosis, which is late and unrelenting. Radiation injury is
a major, dose-limiting complication of therapeutic brain
irradiation and the cause of significant cognitive symp-
toms and loss of quality-of-life. Radiation injury shares
most salient image features with recurrence on com-
puted tomography (CT) and most magnetic resonance
imaging (MRI) sequences [3]. Development of radiation
injury is often delayed weeks to months post-radiation
therapy, mimicking the time course of a potential re-
current tumor, and may be due to radiation damage to
vascular endothelial cells leading to ischemic injury and
demyelinization [4], direct radiation-induced killing of
oligodendrocytes [5, 6], or cytokine-mediated host
immune response [7]. Crucially, protocols for clinical
management of radiation necrosis and recurrent tumor
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are incompatible, making their differential diagnosis an
important, yet unmet clinical need.
Positron emission tomography using [18F]fluorodeoxy-
glucose (FDG), [18F]fluorothymidine [8, 9], [11C]methio-
nine [10, 11], [11C]choline [12], and MRI sequences such
as diffusion-weighted imaging [13], perfusion imaging
[14], MR spectroscopy [15], and fluid-attenuated inver-
sion recovery [16] has been investigated to differentiate
radiation injury from recurrent tumor in human patients
with variable sensitivity and specificity. Current diagnos-
tic protocols using MRI and FDG-PET require one or
more follow-up imaging studies [2], delaying diagnosis
and definitive choice of treatment.
Poly(ADP-ribose) polymerase (PARP) is a family of
nuclear enzymes associated with DNA-damage response
that are highly expressed in many human cancers,
including several with significant incidence, including
breast [17], lung [18], ovarian, and others [19]. PARP
overexpression may be a side effect of transformation, it
may be an adaptation to high genomic instability [20], or
it may drive tumorigenesis by inflammatory [21] or
other mechanisms [22–24]. Therapeutic inhibition of
PARP has met with success in the clinic, leading to FDA
approval of three small-molecule PARP inhibitors
(olaparib, rucaparib, and niraparib) between 2014 and
2017. As a molecular marker of cancer upregulated dur-
ing tumor evolution, PARP-targeted imaging is a prom-
ising candidate for efficiently distinguishing neoplastic
pathology from other conditions that share hallmarks of
brain tumors, including enhancement and hypermetabo-
lism [25]. Since radiation injury lacks the high prolifera-
tion and genomic instability that would drive, or be
driven by, PARP overexpression, we theorized that radi-
ation injury would not present with elevated PARP ex-
pression. Based on this physiological rationale, we
formulated the hypothesis that PARPi-PET could accur-
ately distinguish radiation injury from recurrent tumor,
and would outperform amino acid PET in differentiating
these two important clinical entities (Fig. 1). Two
current-generation fluorine-18-labeled PET tracers exist
for imaging PARP expression: [18F]PARPi [26] and
[18F]FluorThanaTrace [27], with structural similarities to
olaparib and rucaparib, respectively.
Amino acid PET was selected as an imaging agent for
comparison to [18F]PARPi-PET because of multiple prior
human and animal studies in differentiating radiation
injury from tumor and the strong molecular rationale
for its effectiveness in this setting [28–30]. To support
the metabolic demands of proliferation and invasion,
cancers may overexpress various solute transporters to
draw useful substrates into the cell. Among these is the
CD98-LAT1 heterodimeric amino acid transporter, which
facilitates transmembrane diffusion of large, neutral amino
acids in a sodium-independent manner [31, 32]. Among
radiotracers reasonably specific for the LAT1 transport
system [33, 34], [18F]FET was chosen due to its relatively
straightforward synthesis.
Here, we present preclinical data showing that experi-
mental murine radiation necrosis does not present with
elevated levels of PARP1 expression and is not [18F]PAR-
Pi-avid in vivo. We further show that [18F]PARPi-PET
outperforms [18F]FET-PET in distinguishing radiation
injury from focal intracranial xenografts.
Methods
General
All animal experiments were performed in accord-
ance with protocols approved by the Institutional
Animal Care and Use Committees of Memorial Sloan
Kettering Cancer Center (MSK) or Washington University
and followed the National Institutes of Health guidelines
for animal welfare. 4-(4-Fluoro-3-(piperazine-1-carbonyl)b
enzyl)phthalazin-1(2H)-one [35] and 4-(4-fluoro-3-(4-(4-fl
uorobenzoyl)piperazine-1-carbonyl)benzyl)phthalazin-1(2-
H)-one [26] ([19F]PARPi) were synthesized following the
original literature procedures. Other chemicals were
procured from commercial suppliers and used without
further purification. 4,7,13,16,21,24-Hexaoxa-diazabicyclo
[8.8.8]hexacosane (K222), dry dimethyl sulfoxide (DMSO)
over molecular sieves, dry acetonitrile over molecu-
lar sieves, ethyl 4-nitrobenzoate, and miscellaneous
chemicals were purchased from Sigma-Aldrich (St.
Louis, MO). L-tyrosine, O-(2-tosyloxyethyl)-N-trityl,
tert-butyl ester, and (O-(2-fluoroethyl)-L-tyrosine)
hydrochloride ([19F]FET) were purchased from ABX
Fig. 1 Experimental setup and hypothesis for imaging radiation
necrosis and orthotopic brain tumors with [18F]FET-PET and
[18F]PARPi-PET. Due to the molecular properties of each lesion and
tracer, [18F]FET-PET will generate high lesion-to-background contrast
in both tumor and radiation necrosis, while [18F]PARPi-PET will
generate high contrast only in tumor
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(Radeberg, Germany). High-performance liquid chroma-
tography (HPLC) purification and analysis was performed
on a Shimadzu UFLC HPLC system with a DGU-20A
degasser, an SPD-M20A UV detector, an LC-20AB pump
unit, and a CBM-20A communication bus module, with
a LabLogic Scan-RAM radio-TLC/radio-HPLC detector
setup to detect radioactive signal. All averages are pre-
sented as mean ± standard deviation.
Radiochemistry
No-carrier-added [18F]fluoride was produced by the
18O(p,n)18F reaction of 16.5 MeV protons incident on an
18O-enriched water target in a GE Healthcare PETTrace
800 cyclotron. To separate the [18F]fluoride in a form
suitable for nucleophilic fluorination, the 18O-enriched
water containing [18F]fluoride was passed through an
anion-exchange cartridge (Waters Sep-Pak QMA Light),
which was then eluted with 2 mL of 11.95 mM K222 and
20 mM K2CO3 in 4% H2O/acetonitrile into a kiln-dried
V-vial. Water was removed azeotropically by heating at
120 °C under a gentle stream of nitrogen until almost no
visible liquid remained; further rounds of azeotropic dry-
ing were unnecessary and did not affect radiochemical
yields or molar activity.
Radiosynthesis of [18F]PARPi was completed as described
previously, using an optimized three-step, one-pot reaction
with a prosthetic group (Additional file 1: Figure S1a).
Briefly, [18F]4-fluorobenzoic acid was prepared by fluorin-
ation of ethyl 4-nitrobenzoate (500 μg) with [18F]KF-K222
at 120 °C in dry DMSO (100 μL), followed by hydrolysis of
the ethyl ester by addition of 50 μL of 1 M NaOH, followed
by neutralization with 50 μL of 1 M HCl. HBTU (10 mg),
triethylamine (20 μL), and 4-(4-fluoro-3-(piperazine-1-car-
bonyl)benzyl)phthalazin-1(2H)-one (2 mg) were added to
the reaction vessel along with 100 μL DMSO and stirred at
room temperature for 30 s. After adding 400 μL aceto-
nitrile and 1 mL water, the crude reaction was purified on
semi-preparative C6-phenyl reversed-phase HPLC using a
7:3 water/acetonitrile isocratic method (Waters Gemini
C6-Phenyl, 5 μm, 10 × 250 mm, 5 mL/min). The collected
HPLC peak (31–32 min, 5–6 mL) was diluted 10:1 with
water, trapped on a C18 Sep-Pak Light cartridge, eluted
with 400 μL of ethanol, and diluted in sterile normal saline,
affording [18F]PARPi in consistent, acceptable radiochem-
ical yield (22 ± 11%, not decay corrected), radiochemical
purity (99%), and molar activity (> 15 GBq/μmol).
Chemical identity of the radiopharmaceutical was
confirmed by co-elution on HPLC with an analytic-
ally identified nonradioactive [19F]PARPi standard
(Additional file 1: Figures S2 and S3).
Radiosynthesis of [18F]FET was completed as de-
scribed in the literature [36], modifying the procedure
slightly to accommodate manual synthesis (Additional file 1:
Figure S1b). Briefly, a commercially available precursor,
6 mg of L-tyrosine, O-(2-tosyloxyethyl)-N-trityl, tert-butyl
ester (ABX, Radeberg, Germany) was fluorinated directly
by heating at 85 °C with [18F]KF-K222 in 500 μL of dry
acetonitrile. Solvent was removed under gentle nitrogen
flow at 85 °C, followed by removal of protecting groups on
the amino acid moieties by heating at 75 °C with 1 mL of a
1:2 mixture of trifluoroacetic acid and 1,2-dichloroethane.
After cooling to room temperature and adding 3 mL di-
chloromethane, the labeled amino acid was separated from
organic components by trapping it on a silica cartridge
(Waters Sep-Pak Silica Light). The cartridge was washed
with 5 mL of 1:1 diethylether/hexanes, dried with nitrogen
for 3 min, and then eluted with glycine buffer (2 mL,
0.5 M, pH 9.5) and the reaction product purified on
semi-preparative C18 reversed-phase HPLC using a 2:98
ethanol/water isocratic method (Waters Gemini C18,
5 μm, 10 × 250 mm, 3 mL/min). The collected HPLC peak
(22–24 min, 6–7 mL) was diluted in sterile normal saline,
affording [18F]FET with good radiochemical yield (43 ±
22%, not decay corrected), radiochemical purity (99%), and
molar activity (> 15 GBq/μmol). Chemical identity of the
radiopharmaceutical was confirmed by co-elution on
HPLC with an analytically identified nonradioactive stand-
ard [19F]FET (Additional file 1: Figures S2 and S3).
Cell culture
U251 cells were kindly provided by the laboratory of Dr.
Ronald Blasberg at MSK. U251 cells were maintained in
150 cm2 tissue culture flasks in Eagle’s modified essential
medium supplemented with 10% heat-inactivated fetal
bovine serum, 100 IU/mL penicillin, and 100 μg/mL
streptomycin, stored in a cell culture incubator at 37 °C
and 5% CO2 atmosphere, changing media every 2 days
and passaging at 70% confluence. Validation of cell line
identity by STR fingerprinting was performed by MSK’s
Integrated Genomics Core (Additional file 1: Table S1).
Animal models
Mice were irradiated at Washington University. To
generate mice with experimental radiation necrosis, 6-
to 8-week-old, female BALB/c mice (n = 10; Harlan;
Indianapolis, IN) were irradiated with the Leksell
Gamma Knife (GK) Perfexion™ (Elekta AB; Stockholm,
Sweden), as described previously [37]. Mice were anes-
thetized with a mixture of ketamine (25 mg/kg) and
xylazine (5 mg/kg), injected intra-peritoneally 5 min
before the start of irradiation, supported on a specially
designed platform mounted to the stereotactic frame
that attaches to the treatment couch of the instrument,
and 50 Gy (at 50% isodose) in a single fraction was deliv-
ered to the left cerebral hemisphere. This treatment
induces radiation necrosis on an experimentally tractable
time scale (progressing over 4–12 weeks following ir-
radiation) in BALB/c mice [37].
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To generate mice with intracranial U251 tumors, 6-to
8-week old, outbred female homozygous athymic nude
mice (Foxn1nu/nu; n = 10; ENVIGO, East Millstone, NJ)
were anesthetized with 2% isoflurane in 2 L/min medical
air and placed in the frame of a Stoelting Digital New
Standard stereotactic device (Stoelting, Wood Dale, IL)
on a rodent warming pad with maintenance anesthesia
delivered by nose cone. A paramedian scalp incision was
created, and subperiosteal dissection exposed the anterior
part of the coronal and sagittal sutures. Using only the
beveled tip of a sterile 25-G needle, a craniotomy was cre-
ated 2 mm lateral and 1 mm anterior to the bregma. A
5-μL Hamilton syringe with a 28-G flat tip needle,
mounted to the stereotactic arm, was gently inserted
through the craniotomy to a depth of 3 mm, and U251
cells (5 × 105 in 1.5 μL of sterile phosphate-buffered saline)
were injected slowly over 5 min. After completion of the
injection, the syringe was left in place for an additional
5 min to allow intracranial pressure to equalize, prevent-
ing reflux of the cells out of the craniotomy and the
formation of extracranial tumor.
Imaging
Brain MRI scans were performed on a 7-T small animal
MRI scanner (Bruker Biospin Corp., Billerica, MA)
equipped with a 12-cm inner diameter gradient (Resonance
Research Inc., Billerica, MA) with 640 mT/m maximum
gradient amplitude. A custom-built 32-mm quadrature
radiofrequency (RF) body coil (Stark Contrast MRI Coils
Research, Erlangen, Germany) was used for RF excitation
and detection with Bruker Avance electronics. The animals
were anesthetized by 2% isoflurane in oxygen, and animal
respiration during MRI was monitored by a physiological
monitoring system (SA Instruments, Stony Brook, NY).
For positioning, gradient-echo scout images of the brain
along three orthogonal orientations were first acquired.
The brain T2-weighted rapid acquisition with refocused
echoes (RARE) axial scan was performed with 22 slices
with 0.7-mm slice thickness covering the whole brain,
repetition time (TR) = 2.37 s, echo time (TE) = 50 ms, 88 ×
140 μm2 in-plane resolution, and approximately 14 min of
acquisition. For the Gd-enhanced scan, Magnevist (Bayer
Healthcare, Wayne, NJ) at a dose of 0.1 mmol/kg was
injected via tail vein. Fast low-angle shot (FLASH)
gradient-echo images were acquired immediately every
3 min for 15 min after the injection with the following pa-
rameters, TR = 130 ms, TE = 2.4 ms, 0.7-mm slice thick-
ness, and 117 × 117 μm2 in-plane resolution. To determine
contrast-enhancing area in tumor mice, the transaxial slice
DCE-MR image with the largest contrast-enhancing area
was loaded into the Fiji distribution of ImageJ [38] and a
polygonal ROI drawn over the contrast-enhancing region.
For PET/CT imaging, mice were injected with radio-
tracer (7.4–18.5 MBq) through the lateral tail vein 2 h
before imaging. PET/CT imaging was performed under
inhaled isoflurane anesthesia (2% in medical air by pre-
cision vaporizer) on a Siemens Inveon PET/CT scanner
(Siemens, Germany). After acquisition (5–15 min with >
20 million counts/scan), list mode emission data were
sorted into two-dimensional sinograms via Fourier rebin-
ning. Data were normalized to correct for non-uniform
detector response, dead time count losses, and posi-
tron branching ratio, but no attenuation, scatter, or
partial-volume averaging corrections were applied.
Sinogram data were subsequently reconstructed into
128 × 128 × 159 matrix (0.78 × 0.78 × 0.80 mm3 voxel
dimensions) using 2D ordered subset expectation
maximization (OSEM2D; 4 iterations, 16 subsets).
Image counts per voxel per second were converted to
activity concentrations (Bq/cc or %IA/cc) using a
system-specific calibration factor derived from im-
aging a mouse-sized water-equivalent phantom con-
taining fluorine-18. CT scans were reconstructed
using a modified Feldkamp cone beam reconstruction
algorithm to generate 512 × 512 × 768 voxel image
volumes (0.197 × 0.197 × 0.197 mm3 voxel dimen-
sions). PET/CT images were processed using Inveon
Research Workplace software, with a spherical VOI
with a volume of 50–150 mm3 drawn in the lesion
and in an unlesioned area of the contralateral hemi-
sphere. To prevent partial volume effects suppressing
apparent uptake in animals with very small tumors,
tumor mice with contrast-enhancing regions below
1.5 mm2 on DCE-MR (n = 3 of 10) were excluded
from PET data analysis.
Autoradiography
Mice were sacrificed immediately after imaging by CO2
asphyxiation and cervical dislocation. Brains were dis-
sected by removing the calvarium and gently dissecting
the brain from the lower skull with the tip of a pair of
forceps. Brains were embedded in OCT medium (Fisher
Scientific, Houston, TX) on dry ice and sectioned at
10-μm thickness onto glass slides on a cryostatic micro-
tome. Slides were placed into a cassette pressed against
the pre-blanked storage phosphor plate, separated by a
layer of plastic wrap, and the plate allowed to charge for
ten half-lives at − 20 °C. The phosphor plate was read on
a Typhoon FLA 7000 scanner (GE Healthcare, Port
Washington, NY), and the slides were subjected to
hematoxylin and eosin staining and scanned on a Mirax
slide scanner (Carl Zeiss, Jena, Germany). Images were
processed using Pannoramic Viewer (3DHISTECH Ltd.,
Budapest, Hungary) and the Fiji ImageJ distribution.
Immunohistochemistry
Mice were sacrificed by CO2 asphyxiation, followed by
intracardiac perfusion with phosphate-buffered saline
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and formalin. Brains were then dissected and fixed in 4%
paraformaldehyde for 24 h before dehydration in 70%
ethanol overnight, embedding in paraffin and sectioning.
For PARP1 IHC, staining was performed using a Discov-
ery XT processor (Ventana Medical Systems, Tucson,
AZ). Formalin-fixed, paraffin-embedded 3-μm sections
were deparaffinized with EZPrep buffer, antigen retrieval
was performed with CC1 buffer (Ventana Medical Systems,
Tucson, AZ), and sections were blocked for 30 min with
Background Buster solution (Innovex, Richmond, CA). The
tissue was incubated with anti-PARP1 rabbit polyclonal
antibody (sc-7150, Santa Cruz Biotechnology, Santa Cruz,
CA) for 5 h (0.2 μg/ml), followed by 1 h incubation with
biotinylated goat anti-rabbit IgG (PK6106, Vector Labs,
Burlingame, CA) at a 1:200 dilution. For detection, a DAB
detection kit (Ventana Medical Systems, Tucson, AZ) was
used according to the manufacturer’s instructions. Sections
were counterstained with hematoxylin and coverslipped
with Permount (Fisher Scientific, Pittsburgh, PA, USA).




Irradiated mice developed lateral contrast-enhancing
hyperintense regions in the dosed hemisphere on T2-
and DCE-MR imaging, corresponding to radiation
necrosis-induced edema, by 5 weeks post-irradiation
(Additional file 1: Figure S4). At 9 weeks post-irradiation,
edematous regions had expanded to cover > 60% of the
irradiated hemisphere (Additional file 1: Figure S4) and
mice developed stress and neurological symptoms
(hunching, ataxia, poor grooming). By week 10, two
mice (20%) died spontaneously; other mice were
sacrificed over the course of the imaging experiments.
Mice bearing intracranial U251 xenografts developed
similar lateral contrast-enhancing hyperintense regions
in the engrafted hemisphere on T2- and DCE-MR
imaging, corresponding to edema from disordered
tumor neovasculature. Tumor mice became moribund
at 10–12 weeks post-engraftment.
Immunohistochemistry
Immunohistochemistry indicates that radiation necrosis
lesions and healthy brain express minimal PARP1,
whereas U251 tumors overexpress PARP1 in the nuclei
of tumor cells (Fig. 2).
Autoradiography
Storage phosphor autoradiography of cryosectioned tissue
from animals injected with [18F]PARPi (11.1–18.5 MBq
in 200 μL 5% ethanol in normal saline) and [18F]FET
(11.1–18.5 MBq in 200 μL < 1% ethanol in normal sa-
line) showed differential accumulation of both tracers
in radiation necrosis and tumor (Fig. 3). In radiation
necrosis animals, both [18F]PARPi and [18F]FET uptake
were present on the lesioned side, but at much lower
levels for [18F]PARPi. In U251 tumor animals,
[18F]PARPi uptake was negligible in non-tumor areas
but high in tumor areas, while [18F]FET uptake was
moderate in non-tumor areas and high in tumor areas.
Regions of tracer uptake co-localized with tumor (region
Fig. 2 Anti-PARP1 immunohistochemistry. Staining of transaxial formalin-fixed, paraffin-embedded sections of mice implanted with U251 tumors
(left group) mice with experimental radiation necrosis (right group) reveals high PARP1 expression in the nuclei of tumor cells and low PARP1
expression elsewhere in healthy brain and radiation necrosis
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of abnormal cellularity on H&E) or necrosis (region of
tissue loss and disorganization on H&E). In treatment
naïve animals, [18F]PARPi uptake was near-baseline and
[18F]FET uptake was low but present.
PET imaging
Complete tabular data for PET VOIs are available in
Additional file 1: Tables S2 through S5. In mice with
experimental radiation necrosis, lesion maximum voxel
uptake on [18F]PARPi-PET was not higher than contra-
lateral uptake (ratio: 1.02 ± 0.26 lesion/contralateral
%IA/ccmax ratio; Fig. 4b), while [
18F]FET-PET maximum
voxel uptake corresponded to the contrast-enhancing re-
gion on MR with an uptake ratio of 2.12 ± 0.16 (lesion/
contralateral %IA/ccmax ratio; Fig. 4b, Additional file 1:
Figure S6). In mice with experimental radiation necrosis,
lesion mean uptake on [18F]PARPi-PET was somewhat
higher than contralateral uptake (ratio: 1.47 ± 0.11 lesion/
contralateral %IA/ccmean ratio; Additional file 1: Figure S7a),
while [18F]FET-PET mean uptake ratios were much
higher at 2.46 ± 0.39 (lesion/contralateral %IA/ccmean
ratio; Additional file 1: Figure S7a). [18F]FET-PET
maximum voxel uptake ratios were significantly different
between irradiated and treatment-naïve mice (p < 0.0001,
Fig. 3 Hematoxylin and eosin stains and autoradiography. Hematoxylin and eosin stains (left) and digital storage phosphor autoradiography
(right) of whole transaxial sections of mice with implanted U251 tumors (top row), experimental radiation necrosis (middle row), and naïve mice
(bottom row), injected with [18F]FET (left column) or [18F]PARPi (right column). Autoradiographic scans have been contrast-adjusted for visibility.
Mice were sacrificed 2.5 h post-injection of radiotracer
Fig. 4 PET imaging of experimental murine radiation necrosis. a (left column) DCE-MR and (right column) fused PET/CT transaxial slices of mice
with experimental radiation necrosis, injected with (top row) [18F]PARPi and (bottom row) [18F]FET. b Lesioned-to-contralateral hemisphere %IA/
ccmax ratios for mice in different groups. **Significant at p < 0.005; ****significant at p < 0.0001
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unpaired t test; Fig. 4b), while [18F]PARPi-PET maximum
voxel uptake ratios were not significantly different
between irradiated and untreated mice (p = 0.98, un-
paired t test; Fig. 4b; more images in Additional file 1:
Figure S6).
In mice-bearing focal intracranial U251 xenografts, both
[18F]PARPi and [18F]FET showed tumor accumulation,
which varied widely according to tumor size (Fig. 5,
Additional file 1: Figure S6). Contrast-enhancing areas on
DCE-MR were correlated to tumor-to-background
%IA/ccmax ratios on [
18F]PARPi-PET and [18F]FET-PET
(Pearson’s r > 0.95, Additional file 1: Figure S8 and
Table S6). Visual delineation of the tumor from back-
ground was much easier on [18F]PARPi-PET than
[18F]FET-PET. Quantification of the lesion/contralateral
%IA/ccmax ratios showed higher ratios on [
18F]PARPi-PET
than [18F]FET-PET, for animals imaged on consecutive
days with both tracers (p = 0.028, paired t test; Fig. 5b).
On PET imaging, [18F]PARPi uptake was observed in
gut, liver, spleen, submandibular lymph nodes, and tumor,
consistent with earlier reports [26]. [18F]FET uptake was
observed in liver and bladder and systemically in muscle,
radiation necrosis, and tumor lesions. Earlier reports have
investigated [18F]FET uptake in radiation injury and brain
tumors as well [30, 39, 40]. Notably, we found that sys-
temic [18F]FET uptake was much higher in both tumor
and radiation necrosis mice than in healthy BALB/cJ or
nu/nu mice (Additional file 1: Figure S5).
Discussion
Discrimination of radiation injury from recurrent or
novel tumor in the brain within a single visit represents
an urgent clinical need. Based on the theory that PARP
overexpression is largely neoplasia-specific in adults, we
hypothesized that radiation injury would not present with
elevated levels of PARP1 expression. Consequently, radi-
ation injury should not be significantly [18F]PARPi-avid
(Fig. 1). Immunohistochemistry bore out the first hypoth-
esis, showing that in an experimental model of radiation
necrosis, mice did not develop elevated PARP1 expression
as compared to contralateral or treatment-naïve brain,
while glioblastoma xenografts expressed high levels of
PARP1 in tumor cell nuclei (Fig. 2). This finding is con-
sistent with studies in pediatric diffuse intrinsic pontine
glioma [41] and adult glioblastoma [42], both of which
found enhanced PARP1 expression in clinical samples of
human brain tumors.
Our second hypothesis was confirmed by PET imaging:
[18F]PARPi-PET did not reveal significant lateral uptake in
radiation necrosis mice as compared to healthy controls
despite BBB disruption, while [18F]FET-PET was strongly
accumulated by radiation necrosis in our model. Further-
more, [18F]PARPi tumor to non-tumor ratios were signifi-
cantly higher than [18F]FET tumor to non-tumor ratios in
intracranial U251 xenografts.
The physiological basis for the differences in uptake
between [18F]PARPi and [18F]FET is complex and suited
to further investigation. Human clinical samples of radi-
ation necrosis were shown in one study not to express
LAT1 or its cofactor CD98 outside of endothelial cells
and the occasional reactive astrocyte, while brain cancers
highly express both factors at the tumor cell membrane
[43]. Innate immunity [44] and immune cell infiltration
[45, 46] are known processes in radiation injury of the
brain and may be contributing to amino acid uptake
from blood. Although various immune cells have shown
to exhibit increased system L-mediated amino acid up-
take under stimulated conditions [47–49], several studies
Fig. 5 PET imaging of mice with focal intracranial U251 cell xenografts. a (left column) DCE-MR and (right column) fused PET/CT transaxial slices
of mice with U251 tumor, injected with (top row) [18F]PARPi and (bottom row) [18F]FET. b Lesioned-to-contralateral hemisphere %IA/ccmax ratios
for mice in different groups. *Significant at p < 0.05
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demonstrated no increase in [18F]FET uptake in animal
models of inflammation [50–52]. Perhaps more likely,
low-affinity interactions may increase the residence time
of tracers in cellular or extracellular compartments,
causing [18F]FET to build up in the necrotic lesion.
Therefore, both [18F]FET and [18F]PARPi uptake in our
radiation necrosis model could be influenced by perfu-
sion and blood volume, while [18F]FET uptake in radi-
ation necrosis may additionally be transporter-mediated
due to infiltration of the lesion by immune cells.
Furthermore, [18F]PARPi’s nuclear target is present at
high levels in the tumor lesion and almost completely
absent in both healthy tissue and the necrotic lesion.
The role of the PGP1 (also known as MDR1) multidrug
efflux transporter is also potentially important in im-
proving [18F]PARPi contrast in healthy brain regions.
Expressed on the apical membrane of brain capillary
endothelial cells, PGP1 regulates transcellular transport
of a wide range of hydrophobic and amphipathic solutes
[53]. [18F]PARPi is an olaparib analogue with a cyclopro-
pamide moiety replaced with a parafluorobenzamide,
and olaparib is a substrate of PGP1, with expression
of PGP1 being a mechanism for olaparib resistance
in tumor cells [54]. In both contrast-enhancing and
non-contrast-enhancing regions, PGP1 activity may
improve clearance of unspecifically bound material by re-
moving drug that is not being retained by its target.
Additionally, disruption of the BBB will reduce PGP1
activity and further enhance the specific retention of
[18F]PARPi in PARP1 expressing brain lesions.
Conclusions
Using mouse models of radiation necrosis and glioblast-
oma, we have demonstrated that PET imaging with
[18F]PARPi can distinguish between these entities. The
physicochemical properties of [18F]PARPi combine to re-
duce its uptake in regions, both necrotic and healthy,
where its target is not expressed. Furthermore, PARP
overexpression as a biomarker in the developed brain may
be more specific to neoplasia than hypermetabolism of
[18F]FET. Potentially efficient discrimination between re-
current tumor and radiation injury represents an added
value for PARPi-PET and adds to the body of evidence
supporting future clinical translation of this tracer.
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